

## *Why carry out this study?*

- The European Cubicin® Outcome Registry and Experience (EU-CORE) was designed to collect real-world data on patients treated with daptomycin.
- The present analysis evaluated the effectiveness and safety of high doses of daptomycin when administered for a variety of Gram-positive infections; 1097 patients received daptomycin doses >6 mg/kg/day.

## *What was learned from the study?*

- The overall clinical success rate (cured or improved) was 82.0%; numerically higher clinical success rate was observed for endocarditis and foreign body/prosthetic infection, as well as for coagulase-negative staphylococcal and enterococcal infections, with high-dose daptomycin.
- Daptomycin was well tolerated at doses >6 mg/kg/day, with no new or unexpected safety findings.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novartis Pharma AG. Medical writing assistance for this study was provided by Jitendriya Mishra (Novartis Healthcare Pvt. Ltd., Hyderabad, India), Sai Krishnaveni Chevoor (Novartis Healthcare Pvt. Ltd., Hyderabad, India), and Farid Khalfi (Novartis Ireland Ltd., Dublin, Ireland). For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).